AptarGroup
ATR
120.43
+0.18
+0.15%
AptarGroup
US · ATR
#1713 by market cap
Listed 1970
120.43
+0.18
+0.15%
Live - 5344 symbols - heartbeat 223s ago
· 2026-10-08 08:16
Pre-market
120.70
+0.22%
After-hours
120.43
0.00%
- Market cap
- 7.66B
- P/E (TTM)i
- 21.74
- P/Bi
- 2.91
- EPSi
- 5.89
- Div yieldi
- 1.57%
- 52W posi
- 42%
Reader sentiment
Are you bullish or bearish on ATR?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Rating change
DBS Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $170Market Newswire · 2026/3/19
-
Rating change
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $145Market Newswire · 2026/6/12
-
Rating change
Wells Fargo Downgrades AptarGroup(ATR.US) to Hold Rating, Maintains Target Price $133Market Newswire · 2026/1/6
-
Company notice
AI: Statutory ex post facto disclosure documents (merger) (ATR-Trek Co., Ltd.)JPX · 2025/9/1
-
Rating change
Raymond James Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $160Market Newswire · 2026/7/15
-
Rating change
BofA Securities Upgrades AptarGroup(ATR.US) to Buy Rating, Raises Target Price to $173Market Newswire · 2026/7/14
-
Rating change
BofA Securities Maintains AptarGroup(ATR.US) With Hold Rating, Announces Target Price $142Market Newswire · 2026/1/5
-
Rating change
Analysts' Opinions Are Mixed on These Healthcare Stocks: AptarGroup (ATR) and Contineum Therapeutics, Inc. Class A (CTNM)TipRanks · 2026/7/31
-
Company notice
AI: Statutory Advance Disclosure Documents (merger) (ATR-Trek Co., Ltd.)JPX · 2025/7/22
-
Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee ClearancePR Newswire · 2026/10/1
-
BofA Securities Maintains AptarGroup(ATR.US) With Buy RatingMarket Newswire · 2026/8/1
-
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $155Market Newswire · 2026/8/3
-
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $172Market Newswire · 2026/8/21
-
Rating change
Baird Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $156Market Newswire · 2026/2/9
-
Rating change
BofA Securities Maintains AptarGroup(ATR.US) With Hold Rating, Cuts Target Price to $145Market Newswire · 2026/4/6
-
Rating change
Wells Fargo Upgrades AptarGroup(ATR.US) to Buy Rating, Raises Target Price to $144Market Newswire · 2026/3/20
-
Rating change
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $145Market Newswire · 2026/5/4
-
Rating change
BofA Securities Maintains AptarGroup(ATR.US) With Hold Rating, Maintains Target Price $147Market Newswire · 2026/2/26
-
Rating change
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory RisksTipRanks · 2026/3/26
-
William Blair Maintains AptarGroup(ATR.US) With Hold RatingMarket Newswire · 2026/7/31
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 08:16:30 · For reference only, not investment advice and not tailored to your situation.